Temcard-A 5 mg+40 mg (Tablet)
Unit Price: ৳ 12.00 (3 x 10: ৳ 360.00)
Strip Price: ৳ 120.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Amlodipine besilate telmisartan |
| Company | Aristopharma ltd |
| Also available as |
Indications
- Treatment of hypertension
- Combination therapy for blood pressure management
- Initial therapy for patients requiring multiple drugs for blood pressure control
Pharmacology
- Fixed dose combination of Telmisartan and Amiodipine
- Telmisartan: non-peptide angiotensin receptor blocker (ARB)
- Amiodipine: dihydropyridine calcium-channel blocker (CCB)
- Telmisartan's mechanism of action on AT1 receptor
- Amiodipine's mechanism of action on transmembrane calcium ion influx
Dosage & Administration
- Usual starting dose of 40/5 mg once daily
- Patients requiring larger blood pressure reductions may start with 80/5 mg once daily
- Add-on therapy for patients not adequately controlled with individual components
- Replacement therapy for patients receiving separate amiodipine and telmisartan tablets
- Maximum recommended dose of 80/10 mg once daily
Interaction
- Telmisartan's co-administration with various drugs
- Amiodipine's safe administration with different drug classes
Contraindications
- Hypersensitivity to the product or any of its components
- Pregnancy and lactation
- Biliary obstructive disorders, severe hepatic impairment, hypotension, cardiogenic shock, left ventricle outflow tract obstruction
Side Effects
- Dizziness
- Peripheral edema
- Migraine
- Hypotension
- Cough
- Abdominal pain
- Nausea
- Myalgia
- Erectile dysfunction
- Fatigue
Pregnancy & Lactation
- Pregnancy Categories C and D
- Excretion of telmisartan and amiodipine in human milk
- Consideration of drug importance to the mother when discontinuing nursing
Precautions & Warnings
- Avoid fetal or neonatal exposure
- Correct volume or salt depletion before initiating therapy
- Titration in patients with hepatic or severe renal impairment
- Monitoring for worsening heart failure
- Avoid concomitant use of ACE inhibitor and angiotensin receptor blocker
- Potential risk of myocardial infarction with CCB initiation in patients with severe obstructive coronary artery disease
Use in Special Populations
- No established safety and effectiveness in pediatric patients
- Non-recommended initial therapy for patients aged 75 years and older and hepatically impaired patients
Overdose Effects
- Telmisartan overdose manifestations
- Amiodipine overdose manifestations
- Supportive treatment for symptomatic hypotension
- Hemodialysis ineffectiveness for telmisartan and amiodipine
Therapeutic Class
- Combined antihypertensive preparations
Storage Conditions
- Do not store above 30°C
- Protection from light and high humidity
- Keep out of the reach of children